Cardiovascular manifestations of Sjö grens In contrast to systemic lupus erythematosus and rheumatoid arthritis where cardiovascular problems are a frequent extra-articular disease manifestation cardiovascular disease is not common in Sjö grens syndrome. Disease activity measures do not feature cardiovascular disease. There is however a mounting body of evidence that cardiovascular disease may be more prevalent than in the general population. The mechanisms underlying this are similar to those seen in RA and SLE. Other cardiac manifestations including pericardial effusion and conduction abnormalities have been reported.Respiratory DiseaseLung disease is common in Sjogrens but very variable in severity. Lung disease include airway abnormailities, interstitial disease and lymphoprolifeative disorders. Clinically significant lung disease occurs in 9-20% with a female preponderance. CT abnormalities are found in up to 50% and increase with length of disease duration. The main risk factors for lung disease will be discussed together with pathogenesis, treatment and screening to detect earlier disease. Disclosures: The author has declared no conflicts of interest. Good work is good for health. For most people, it brings a sense of purpose and social standing as well as financial security. Moreover, there is evidence that unemployment is bad for health and that the children of those out of work are less likely to find productive work themselves. Historically, healthcare providers have measured outcomes that relate to the type of intervention they are recommending: disease activity score, radiographic change, pain according to a visual analogue scale but patients repeatedly report that these outcomes are often of limited relevance to them and that they want treatment that enables them to enjoy a good quality of life and participate in all aspects of life including work. Musculoskeletal disorders are one of the two main causes of incapacity for work in the developed world. Therefore, rheumatologists and the rheumatology MDT should have an important responsibility to consider patients' work participation, ask patients about their ability to work and provide advice, support and interventions where possible to enable their patients to remain in productive work whilst the patient wishes to do so. It is likely that even expensive treatments such as biologic therapies might be considerably more cost-effective if their impact on work participation and role in reducing dependence on benefit payments were taken into account. The DWP and Department of Health have now formed a joint unit and recently issued a white paper: 'Improving Lives' which sets out an ambitious agenda for better integration of health and work services. This lecture will update clinicians on the political developments and seek to make the case for us all to take more responsibility for enabling our patients to seek productive work if they wish to do so. Disclosures: The author has declared no conflicts of interest. Rheumatologists have long considered psoriatic arthritis (PsA) and osteoarthritis (OA) as two completely distinct arthropathies. Simplistically put, OA has been conceptualised in relation to joint degeneration, whereas PsA has been primarily viewed in terms of joint inflammation. Due of its heterogeneous clinical profile and the possibility of involvement of the axial skeleton, Moll and Wright originally grouped PsA under the spectrum of the spondylarthropathies (SpA). While many of the manifestations of PsA are shared with the other SpAs, DIP joint disease is very typical of PsA. This can cause a clinical dilemma, as DIP joint arthropathy is also characteristic of OA. It was proposed more than a decade ago that enthesitis may be the primary lesion in PsA and SpA. Likewise, several experimental studies have shown that spontaneous knee OA can start in the ligament and enthesis and not the articular cartilage, thus providing proof of principle of similar micro-anatomical topography for disease onset. Studies in the generalised form of human hand OA have also shown that the ligaments and enthesis are the sites of the earliest discernible pathology. Collectively this has resulted in a mechanistic anatomical classification of OA that recognises that the generalised form of disease that was previously designated as idiopathic appears to have an enthesis-associated micro-anatomical basis. MRI of peripheral joints has long demonstrated a capsular pattern of inflammation in PsA as well as evidence for diffuse enthesitis related to pathology in a proportion of patients. Also, it may be impossible to clearly differentiate OA from PsA DIP disease, with both seeming to have prominent abnormalities in the entheses and ligaments. Studies have noted that enthesitis-related bone oedema seen in PsA is also common in OA. With respect to spinal disease, an association was evident, with bone oedema at the enthesis attachment observed occasionally in healthy subjects, OA and SpA. Imaging, in particular MRI, has highlighted how some forms of generalised OA and PsA may afflict the same anatomical territory, namely the enthesis, with genes and environment modifying the clinical phenotype. While degeneration or inflammation may be clearly discernible at the two extremes, there may be a group of patients where differentiation is impossible. Appreciating OA-PsA overlap disease may help with optimal management and apparent biologic therapy failure in PsA. Disclosures: The author has declared no conflicts of interest.
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